SCHEMBL149592

SCHEMBL149592

CCCCC(N)(C(=O)O)C(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
MAPK1 P28482 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
CYP3A4 P08684 1/20 0.49
TSHR P16473 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.46
HIF1A Q16665 1/20 0.46
CETP P11597 3/20 0.43
CTSL P07711 1/20 0.42
CTSS P25774 1/20 0.42
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KMT2A Q03164 1/20 0.41
SLC15A1 P46059 1/20 0.40
LMNA P02545 1/20 0.40
MBOAT4 Q96T53 1/20 0.40
KIF11 P52732 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2963546 0.94 CETP (0.48) ALDH1A1MAPK1TDP1L3MBTL1CYP3A4
SCHEMBL8674203 0.94 CETP (0.48) ALDH1A1MAPK1TDP1L3MBTL1CYP3A4
SCHEMBL7440964 0.91 ALDH1A1 (0.49) ALDH1A1MAPK1TDP1L3MBTL1CYP3A4
SCHEMBL28362146 0.91 ALDH1A1 (0.49) ALDH1A1MAPK1TDP1L3MBTL1CYP3A4
SCHEMBL28366123 0.91 ALDH1A1 (0.49) ALDH1A1MAPK1TDP1L3MBTL1CYP3A4
SCHEMBL27484782 0.87 SMN1; SMN2 (0.47) ALDH1A1MAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL10855149 0.87 SMN1; SMN2 (0.47) ALDH1A1MAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL10855143 0.87 SMN1; SMN2 (0.47) ALDH1A1MAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL5711297 0.86 GRM2 (0.48) ALDH1A1MAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL1167642 0.86 SMN1; SMN2 (0.46) ALDH1A1MAPK1TDP1L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788797-B1 CONTACT LENSES WITH ENZYMATICALLY DEGRADABLE COATINGS THEREON ALCON INC (CH) 2023-06-07 EP disclosed
US-20180015170-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC (US) 2018-01-18 US disclosed
CN-106957316-A Oxazolidone quinolone hybrid antibiotics 莫弗凯姆联合化学股份公司 2017-07-18 CN disclosed
EP-2471774-B1 Piperidinyl derivatives as modulators of chemokine receptor activity BRISTOL MYERS SQUIBB CO (US) 2016-08-24 EP disclosed
US-20160082111-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2016-03-24 US disclosed
EP-2811980-A1 POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE Cerulean Pharma Inc. (US) 2014-12-17 EP disclosed
EP-2812008-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY Cerulean Pharma Inc. (US) 2014-12-17 EP disclosed
US-20140328919-A1 POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE CERULEAN PHARMA INC. (US) 2014-11-06 US disclosed
US-20140328918-A1 METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS CERULEAN PHARMA INC. (US) 2014-11-06 US disclosed
US-20140286873-A1 POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE CERULEAN PHARMA INC. (US) 2014-09-25 US disclosed
US-7985861-B2 Piperidinyl derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2011-07-26 US disclosed
WO-2011063421-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. (US) 2011-05-26 WO disclosed
US-20090298833-A1 PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2009-12-03 US disclosed
US-7601844-B2 Piperidinyl derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-13 US disclosed
EP-2049486-A2 PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2009-04-22 EP disclosed
US-20070208056-A1 PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2007-09-06 US disclosed
WO-2007092681-A2 PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2007-08-16 WO disclosed
EP-1778652-A2 COMPOSITIONS AND METHODS COMPRISING PROTEINASE ACTIVATED RECEPTOR ANTAGONISTS EntreMed, Inc. (US) 2007-05-02 EP disclosed
US-20060063930-A1 Compositions and methods comprising proteinase activated receptor antagonists ENTREMED, INC. 2006-03-23 US disclosed
WO-2006023844-A2 COMPOSITIONS AND METHODS COMPRISING PROTEINASE ACTIVATED RECEPTOR ANTAGONISTS ENTREMED, INC. (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160082111-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY SDCBP, DDOST, DSC1 ALDH1A1 3011/4885MAPK1 4685/4885TDP1 879/4885
US-20090298833-A1 PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCR1, CCR2, CCR3 ALDH1A1 263/4885MAPK1 482/4885TDP1 3069/4885
US-20070208056-A1 PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCR1, CCR2, CCR3 ALDH1A1 263/4885MAPK1 482/4885TDP1 3069/4885
US-20140286873-A1 POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE LPXN, POLI, BRCA1 ALDH1A1 1992/4885MAPK1 4761/4885TDP1 612/4885
US-20140328918-A1 METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS HLA-DRB1, TSG101, IAPP ALDH1A1 3058/4885MAPK1 4795/4885TDP1 781/4885
US-20060063930-A1 Compositions and methods comprising proteinase activated receptor antagonists F2RL1, PLAUR, F2R ALDH1A1 4556/4885MAPK1 2644/4885TDP1 3925/4885
US-20140328919-A1 POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE LPXN, POLI, BRCA1 ALDH1A1 1992/4885MAPK1 4761/4885TDP1 612/4885
US-20180015170-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY SDCBP, DDOST, DSC1 ALDH1A1 3011/4885MAPK1 4685/4885TDP1 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.